Preceptor Award: Targeting JAK2-STAT5 Signaling in Prostate Cancer

Project Description Narrative:

Metastatic prostate cancer is typically treated with androgen deprivation therapy (ADT). However, instances of castrate-resistant prostate cancer often result from an inability of ADT to effectively suppress the direct target of ADT: ligand-regulated androgen receptor transcription factor. While new anti-androgen treatments have been developed, patient survival rates only improved by four to six months due to the development of resistance. New knowledge is needed to improve understanding and treatment options that may impact quality and length of life for those with metastatic prostate cancer.

Through this award, a student research experience will expand the scope of a sub-award to the AHW-funded Cancer Cell Biology Research Program by studying Apalutamide-resistant prostate cancer growth.

Student: Paul Beinhoff, M1, Medical College of Wisconsin School of Medicine